Anavex Life Sciences Corp. (AVXL)
Largest Insider Buys in Sector
AVXL Stock Price History Chart
AVXL Stock Performance
About Anavex Life Sciences Corp.
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson's disease; and preclinical clinical trials to treat epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, …
Insider Activity of Anavex Life Sciences Corp.
Over the last 12 months, insiders at Anavex Life Sciences Corp. have bought $32,919 and sold $374,972 worth of Anavex Life Sciences Corp. stock.
On average, over the past 5 years, insiders at Anavex Life Sciences Corp. have bought $29,305 and sold $3.07M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Thomas Steffen (director) — $22,600. Donhauser Peter D.O. (director) — $10,319.
The last purchase of 2,835 shares for transaction amount of $10,319 was made by Donhauser Peter D.O. (director) on 2024‑06‑14.
List of Insider Buy and Sell Transactions, Anavex Life Sciences Corp.
| 2024-06-14 | director | 2,835 0.0033% | $3.64 | $10,319 | +51.19% | |||
| 2024-05-15 | director | 5,000 0.0059% | $4.52 | $22,600 | +22.16% | |||
| 2024-03-28 | Sale | President and CEO | 73,380 0.0911% | $5.11 | $374,972 | -11.98% | ||
| 2023-06-28 | Sale | President and CEO | 268,000 0.3424% | $7.98 | $2.14M | -24.50% | ||
| 2022-05-25 | Sale | 50,000 0.0643% | $9.06 | $453,000 | +8.46% | |||
| 2021-06-29 | Sale | President and CEO | 51,620 0.0805% | $26.00 | $1.34M | -28.27% | ||
| 2021-06-29 | Sale | PFO and Treasurer | 166,696 0.2651% | $26.53 | $4.42M | -28.27% | ||
| 2021-05-21 | Sale | director | 145,000 0.2057% | $11.70 | $1.7M | +49.44% | ||
| 2021-05-17 | director | 1,000 0.0014% | $10.93 | $10,930 | +54.43% | |||
| 2021-02-24 | Sale | director | 145,500 0.2172% | $12.66 | $1.84M | +40.94% | ||
| 2021-02-19 | director | 1,165 0.0017% | $12.67 | $14,760 | +38.92% | |||
| 2018-03-07 | President and CEO | 1,360 0.0031% | $2.92 | $3,971 | -13.15% | |||
| 2018-03-06 | President and CEO | 1,450 0.003% | $2.73 | $3,959 | -14.33% | |||
| 2018-03-05 | President and CEO | 1,500 0.0034% | $2.63 | $3,945 | -4.20% | |||
| 2018-03-02 | Director, President & CEO | 1,650 0.0034% | $2.41 | $3,977 | -3.85% | |||
| 2017-10-25 | President and CEO | 375 0.0009% | $4.39 | $1,646 | -36.81% | |||
| 2017-10-24 | President and CEO | 375 0.0009% | $4.92 | $1,845 | -41.40% | |||
| 2017-10-19 | President and CEO | 375 0.0008% | $4.49 | $1,684 | -40.47% | |||
| 2017-10-17 | President and CEO | 375 0.0009% | $4.27 | $1,601 | -34.35% | |||
| 2017-10-13 | President and CEO | 750 0.0017% | $4.22 | $3,165 | -34.58% |
Insider Historical Profitability
| MISSLING CHRISTOPHER U | President and CEO | 1250210 1.4744% | $5.67 | 39 | 3 | +42.62% |
| Thomas Steffen | director | 5000 0.0059% | $5.67 | 1 | 0 | |
| Donhauser Peter D.O. | director | 5000 0.0059% | $5.67 | 3 | 0 | +46.67% |
| Skarpelos Athanasios | 1306458 1.5407% | $5.67 | 1 | 6 |
Institutional Investor Ownership
| State Street | $37.15M | 8.62 | 7.3M | +100.37% | +$18.61M | <0.01 | |
| BlackRock | $33.83M | 7.85 | 6.65M | -0.38% | -$129,983.33 | <0.01 | |
| The Vanguard Group | $22.47M | 5.22 | 4.41M | +1.24% | +$275,033.05 | <0.0001 | |
| Geode Capital Management | $8.72M | 2.02 | 1.71M | +2.84% | +$241,115.07 | <0.01 | |
| Bank of America | $4.33M | 1.01 | 851,128 | +315.31% | +$3.29M | <0.0001 |